Crossmark

Response to “Letter to the Editor” Regarding Odin P, et al. 2025 ‘Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs’

Crossref DOI link: https://doi.org/10.1007/s40120-025-00876-x

Published Online: 2025-12-23

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taerud, Christoffer https://orcid.org/0009-0004-5146-788X
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2025-12-23
More Information

Article History

Received: 27 October 2025

Accepted: 2 December 2025

First Online: 23 December 2025

Declarations

:

: Christoffer Taerud is an AbbVie employee and may hold AbbVie stock.

: This response letter is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below